# Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors

> **NCT06408688** · PHASE4 · RECRUITING · sponsor: **University Hospital, Basel, Switzerland** · enrollment: 100 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** Immune checkpoint inhibitors plus Iscador® Qu.
- **DRUG:** Immune Checkpoint Inhibitors

## Key facts

- **NCT ID:** NCT06408688
- **Lead sponsor:** University Hospital, Basel, Switzerland
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-24
- **Primary completion:** 2026-11
- **Final completion:** 2026-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06408688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06408688, "Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06408688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*